INDEX OF SUBJECTS FOR VOLUME 32

Acetazolamide sensitivity
  heterotrophic bacteria, 1
  neisseriae, 1
Adenylate cyclase
  in *B. pertussis* infection, 173
Adherence
  E. coli, in urinary tract infection, 135
  H. pylori to polymorphonuclear leucocytes, 93
  S. aureus to epidermal cells, 9
  S. aureus to fibronectin, 195
  S. aureus to HEp2 cells, 195
  S. epidermidis, in urinary tract infection, 135
  S. saprophyticus, in urinary tract infection, 135
Aeromonas
  isolation from faecal specimens, 49
  role in diarrhoeal disease, 45
  selective culture media, 49
Agglutinogens, of *B. pertussis*, 63
AIDS (acquired immune deficiency syndrome)
  detection of mycobacteria in blood, 271
  detection of toxoplasma DNA, 25
Airways diseases, chronic, 169
Amino-acid sequence analysis, 153
Amoebiasis
  diagnosis by micro-ELISA, 87
Ampicillin
  resistance of *E. coli*, 223
  sensitivity of *Aeromonas* spp., 49
Anaerobes, in necrotic tumours, 207
Antibiotic resistance
  ampicillin, and *E. coli*, 223
  ceftazidime, and *K. oxytoca*, 131
  cephalosporins, and *K. oxytoca*, 131
  cephalothin, and *E. coli*, 223
  of *E. coli*, and metal ions, 223
  kanamycin, and *E. coli*, 223
  methicillin, and *S. aureus*, 195
  streptomycin, and *S. hyicus*, 201
  trimethoprim, and *E. coli*, 153, 159
Antibiotics and other antimicrobial substances
  ampicillin, and *Aeromonas* spp., 49
  ciprofloxacin, intraphagocytic activity, 15
  ciprofloxacin, and *S. marcescens*, 211
  difloxacin, and *S. marcescens*, 211
  fleroxacin, and *E. coli*, 83
  fleroxacin, intraphagocytic activity, 15
  methicillin, and *S. aureus*, 195
  nalidixic acid, and *S. marcescens*, 211
  norfloxacin, and *S. marcescens*, 211
  ofloxacin, and *S. marcescens*, 211
  pefloxacin, and *E. coli*, 83
  pefloxacin, intraphagocytic activity, 15
  polymyxin extraction method, 255
  susceptibility of coagulase-negative staphylococci, 115
Antibodies
  against *B. pertussis* adenylate cyclase, 173
  against *E. coli* cytotoxic necrotising factor, 73
  against *H. pylori*, 105
  against *N. meningitidis*, 275
  against *P. multocida*, 55
  see also Monoclonal antibodies
Antigens
  cell surface, of *B. pertussis*, 63
  cell-wall-derived polypeptides of mycobacteria, 263
  of *E. histolytica*, 87
  expression by ureaplasmas, 163
  of *L. major* promastigotes, 189
  outer membrane proteins of *N. meningitidis*, 275
  outer membrane proteins of *P. multocida*, 55
Antisera, against *E. histolytica*, 87
Antitoxins, against cholera toxins, 33
Arsenate resistance, of *E. coli*, 223

Bacteriophage *see* Phage
Bacteroides spp., in necrotic tumours, 207
Bile salts, sensitivity of *Aeromonas* spp., 49
Biotinylation
  cell wall antigens of mycobacteria, 263
Biotyping
  coagulase-negative staphylococci, 115
Blood
  rapid detection of mycobacteria, 271
Bordetella pertussis
  anti-adenylate cyclase antibodies, 173
  immuno-electronmicroscopy of agglutinogens, 63
  vaccines, 63, 173
BOOKS RECEIVED
  A colour atlas and textbook of the histopathology of mycotic diseases (F W Chandler, W Kaplan and L Ajello), 71
  Immune responses, virus infections and disease (edited by N J Dimmock and P D Minor), 71
  Microbiological methods (C H Collins, Patricia M Lyne and J M Grange), 71

Cadmium resistance, of *E. coli*, 223
Calcium, in cell culture media, 9
Campylobacter pylori see Helicobacter pylori
Candida
  C. albicans, electrophoretic analysis of chromosomes, 123
  C. albicans, karyotyping system, 123
  electrophoretic analysis of chromosomes, 123
Carbohydrates
  effects on adherence of *S. aureus*, 9
  effects on recovery of *Aeromonas* spp. from faeces, 49
Carbonic anhydrase activity
  in heterotrophic bacteria, 1
  in neisseriae, 1
Ceftazidime, resistance of *K. oxytoca*, 131
Cell culture
  mouse epidermal cells, 9

Cell surface
antigens of *B. pertussis*, 63
hydrophobicity of *H. pylori*, 93
Cell wall
polypeptide antigens of mycobacteria, 263
Cephalothin, resistance of *E. coli*, 223
Chemiluminescence, 189
Cholera toxins
immunobiological relationships, 33
Chromatography
gas, 101
hydrophobic interaction, 19, 93
methotrexate affinity, 153
Chromosomes
of yeasts, electrophoretic analysis, 123
Ciprofloxacin
bactericidal activity against *S. marcescens*, 211
intraphagocytic activity, 15
Corynebacterium diphtheriae
detection of toxin by immunoassay, 247
monoclonal antibody against toxin, 247
Cryptosporidiosis
probable waterborne outbreak, 239
Cryptosporidium
enzyme immunoassay, 233
monoclonal antibody, 233
oocysts, 243, 239, 233
sand filtration of contaminated water, 243
waterborne transmission, 243, 239, 233
Cystic fibrosis, 169
Cytokines
host response to endotoxin, 217
Cytolysis
effects of *V. vulnificus* haemolysin, 39
Cytotoxic necrotising factor, detection by ELISA, 73
Cytotoxicity assay
cytotoxic necrotising factor, 73
toxins of *E. coli*, 73
Cytotoxins
rapid detection methods, 255
Vir, 73

Diarrhoea
in cryptosporidiosis, 239
detection of toxins, 255
infantile, and *E. coli*, 159
role of *Aeromonas* spp., 45
role of *P. shigelloides*, 45
Difloxacin, intraphagocytic activity, 15
Dihydrofolate reductase
plasmid-mediated, and *E. coli*, 153
DNA
amplification, 25
extrachromosomal banding patterns, 115
hybridisation, 25, 115, 145, 271, 255, 179
karyotyping of *C. albicans*, 123
probes, 25, 115, 145
Diphtheria toxin, immunoassay, 247

Electrodialysis
purification of β-lactamase, 131
Electronmicroscopy
agglutinogens of *B. pertussis*, 63
immuno-electronmicroscopy, 63
phages in *H. pylori*, 101
scanning, 135
urinary tract infection, 135
Electrophoresis
clamped homogeneous electric field, 123
gel, of toxoplasma DNA, 123
pulsed field gel, 123
see also PAGE; SDS-PAGE
ELISA
detection of anti-*H. pylori* antibodies, 105
detection of cytotoxic necrotising factor, 73
diagnosis of amoebiasis, 87
micro-ELISA, 87
Endocarditis, 115
Endotoxin
factors in host susceptibility, 217
Entamoeba histolytica
circulating immune complexes, 87
diagnosis of amoebiasis by micro-ELISA, 87
Enteropathogens
in diarrhoeal disease in Nigeria, 45
Enterotoxins
of *E. coli*, 73
of *V. cholerae*, 33
Enzyme immunoassay
for oocysts of *Cryptosporidium*, 243, 233
Epidemiology
characterisation of *C. albicans*, 123
pyocin types of *P. aeruginosa*, 169
role of pyrolysis-mass spectrometry, 283
typing of *Y. enterocolitica*, 179
Epidermal cells
adherence of *S. aureus*, 9
calcium-induced differentiation, 9
Epidermitis, exudative, 201
Escherichia coli
antibacterial effects of 4-quinolones, 83
cytotoxicity assays, 73
detection of cytotoxic necrotising factor, 73
dihydrofolate reductase, 153
fimbriae, 135
in necrotic tumours, 207
pathogenesis in urinary tract infection, 135
phagocytosis by urothelial cells, 135
plasmids, 153
rapid detection of Shiga-like toxin, 255
resistance to antibiotics, 223
resistance to metal ions, 223
trimethoprim resistance, 153, 159
Exotoxins, of *V. vulnificus*, 39

Faecal flora
detection of *Cryptosporidium*, 233
diarrhoeal disease in Nigeria, 45

Fetal specimens
detection of toxoplasma DNA, 25
Fibronectin, adherence of *S. aureus*, 195
Filtration
cryptosporidium oocysts from water, 243
Fimbriae
of *B. pertussis*, 63
of *E. coli*, 135
of salmonellae, 145
Fleroxacin
and *E. coli*, 83
intraphagocytic activity, 15
Fluid secretion, *V. cholerae*-induced, 33
Fluoroquinolones
antibacterial effects, and *E. coli*, 83
bactericidal activity against *S. marcescens*, 211
intraphagocytic activity, 15
Foodstuffs, isolation of *E. coli*, 223
Formica blocks, survival of *S. aureus*, 195
Freeze-thawing techniques, 73

Gastritis, *H. pylori* in, 101, 105
Genes
amplification, 25
fimbrial gene-probing of salmonellae, 145
Gen-probe system, 271
Globotriosyl ceramide, toxin binding, 255
Glomerulonephritis, post-streptococcal acute, 111
Granulocytes
phagocytosis and killing of *S. saprophyticus*, 19
Granulomatous disease, chronic, 15

Haemolysins
of *E. coli*, 73
of *V. vulnificus*, 39
Haemolytic uraemic syndrome, 255
Haemorrhagic colitis, 255
Helicobacter (Campylobacter) pylori
bacteriophages, 101
in gastritis, 101, 105
hydrophobic characterisation, 93
lysogeny, 101
prevalence of antibodies, 105
Heterotrophic bacteria
acetazolamide sensitivity, 1
carbonic anhydrase activity, 1
Histamine release, and *V. vulnificus*, 39
Hybridisation of DNA
detection of mycobacteria, 271
detection of *T. gondii*, 25
detection of toxins, 255
epidemiological typing of *Y. enterocolitica*, 179
fimbrial gene-probing of salmonellae, 145
typing of coagulase-negative staphylococci, 115
Hydrophobicity
of *H. pylori*, 93
of *S. aureus*, 9
of *S. saprophyticus*, 19

Ileal loop
fluid accumulation, and *V. cholerae*, 33
Immune complexes, circulating, 83
Immune response, to *N. meningitidis*, 275
Immunisation
against *B. pertussis*, 173
mice against *C. diphtheriae*, 247
mice against *P. multocida*, 55
Immunoassay
detection of diphtheria toxin, 247
see also Enzyme immunoassay
Immunoblotting
antibodies against *N. meningitidis*, 275
antigens of ureaplasmas, 163
carbonic anhydrase cross-reacting proteins of *N. sicca*, 1
monoclonal antibodies against diphtheria toxin, 247
outer membrane proteins of *P. multocida*, 55
Immunocompromised patients, 15, 25, 271
Immunodiffusion
antigenic relationships of cholera toxins, 33
carbonic anhydrase cross-reacting proteins of *N. sicca*, 1
Immuno-electronmicroscopy
agglutinogens of *B. pertussis*, 63
Immunofluorescence microscopy, 243
Immunoglobulin G, IgG
against *N. meningitidis*, 275
anti-amoebic, 83
gold labelling, 63
monoclonal, against diphtheria toxin, 247
opsonophagocytosis assays, 19
Immunogold labelling
cell surface antigens of *B. pertussis*, 63
Interferon-γ, 217
Iron-regulation
outer membrane proteins of *N. meningitidis*, 275

Kanamycin resistance, of *E. coli*, 223
Karyotyping system, for *C. albicans*, 123
Klebsiella
K. oxytoca, ceftazidime resistance, 131
K. oxytoca, β-lactamase TEM-E2, 131
K. pneumoniae, in necrotic tumours, 207

β-Lactamase, of *K. oxytoca*, 131
Lactate dehydrogenase activity of *V. vulnificus*, 39
Leishmania major
antigens, and polymorphonuclear leucocytes, 189
Lipoteichoic acid
role in adherence of *S. aureus*, 9
Liver abscess, amoebic, 87
Lysogeny, and *H. pylori*, 101

Mast cells
cytolytic action of *V. vulnificus* haemolysin, 39
Media
and calcium-induced cell differentiation, 9
radiometric broth culture (Bactec 13A), 271
for recognition and selection of *Aeromonas* spp., 49

Mercury resistance, of *E. coli*, 223
Metal ions, resistance of *E. coli*, 223
Methicillin resistance, and *S. aureus*, 195
Micro-ELISA, in diagnosis of amoebiasis, 87
Monoclonal antibodies
  against *Cryptosporidium* oocysts, 233
  against diphtheria toxin, 247
  against Shiga-like toxin, 255
  against Shiga toxin, 255
  against ureaplasmas, 163
Mouse model
  urinary tract infection, 135
Mycobacterium
  cell-wall-derived polypeptide antigens, 263
  infections, and AIDS patients, 271
  M. avium, rapid detection in blood, 271
  M. tuberculosis, rapid detection in blood, 271

Nalidixic acid, and *S. marcescens*, 211
Neisseria
  acetazolamide sensitivity, 1
  carbonic anhydrase activity, 1
  N. gonorrhoeae, carbonic anhydrase activity, 1
  N. meningitidis, immune responses, 275
  N. meningitidis, iron-regulated outer membrane proteins, 275
  N. sicca carbonic anhydrase activity, 1
Neutralisation tests
  enterotoxins of *V. cholerae*, 33
Neutrophils
  intracellular bioactivity of fluoroquinolones, 15
Norfloxacin, and *S. marcescens*, 211

Oestrogen
  binding by trichomonads and bacteria, 227
  effects on trichomonads and bacteria, 227
Ofloxacin, and *S. marcescens*, 211
Oocysts, of *Cryptosporidium*, 243, 239
Opsonisation
  S. saprophyticus by human serum, 19
Outer membrane protein, OMP
  iron-regulated, of *N. meningitidis*, 275
  of *P. multocida*, immunogenicity, 55
Oxygen free radicals, 217, 189

PAGE
  dihydrofolate reductase of *E. coli*, 153
  see also Electrophoresis; SDS-PAGE
Partitioning, aqueous two-phase, 93
Pasteurella multocida
  immunogenicity of outer membrane proteins, 55
Pefloxacin
  and *E. coli*, 83
  intraphagocytic activity, 15
Peptic ulcer, and *H. pylori*, 101, 105
Phage
  in *H. pylori*, 101
  typing, of coagulase-negative staphylococci, 115
  typing, of salmonellae, 283

Phagocytosis
  E. coli, by urothelial cells, 135
  intraphagocytic activity of fluoroquinolones, 15
  S. aureus, by human neutrophils, 15
  S. saprophyticus, by human granulocytes, 19
Plasmids
  ceftazidime resistance in *K. oxytoca*, 131
  streptomycin resistance of *S. hyicus*, 201
Plesiomonas shigelloides
  role in diarrhoeal disease, 45
Polymerase chain reaction
  in detection of toxoplasma DNA, 25
Polymorphonuclear leucocytes, PMNLs
  adherence of *H. pylori*, 93
  effect of antigens of *L. major*, 189
Polymyxin extraction, 255
Polyunsaturated fatty-acids, PUFA, 217
Propionibacterium acnes, in necrotic tumours, 207
Protein
  M protein typing, 283
  see also Outer membrane proteins
Protein-A gold labelling, 63
Proteus, carbonic anhydrase activity, 1
Protoplast transformation, 201
Pseudomonas
  carbonic anhydrase activity, 1
  P. aeruginosa, in necrotic tumours, 207
  P. aeruginosa, pyocin types, 169
Pyocin typing, of *P. aeruginosa*, 169
Pyrolysis-mass spectrometry
  epidemiological typing of salmonellae, 283
  epidemiological typing of *S. pyogenes*, 283

4-Quinolones
  antibacterial effects, and *E. coli*, 83
  bactericidal activity against *S. marcescens*, 211
  intraphagocytic activity, 15

Radioassay
  intracellular bioactivity of fluoroquinolones, 15
Radiolabelling
  HeLa cell toxin assay, 93
  H. pylori, 93
Radiometric broth culture method, 271
Restriction endonuclease analysis
  coagulase-negative staphylococci, 115
  resistance plasmid of *S. hyicus*, 201
Restriction fragment-length polymorphisms
  salmonellae, 145
  Y. enterocolitica, 179

Salmonellae
  biotyping, 145
  fimbrial gene-probing, 145
  Gallinarum serotypes, 145
  phage typing, 283
  Pullorum serotypes, 145
  pyrolysis-mass spectrometry, 283
Salt aggregation test, 19
Scabies, 111

SDS-PAGE
cell wall antigens of mycobacteria, 263
outer membrane protein of *N. meningitidis*, 275
outer membrane proteins of *P. multocida*, 55
Septicaemia, meningococcal, 275
Sera
from patients with meningococcal disease, 275
opsonisation of *S. saprophyticus*, 19
Serotyping
coagulase-negative staphylococci, 115
β-haemolytic streptococci, 111
Serratia
carbonic anhydrase activity, 1
S. marcescens, and 4-quinolones, 211
Shiga-like toxin-I, rapid detection, 255
Shiga toxin, rapid detection, 255
Shigella dysenteriae
rapid detection of Shiga toxin, 255
Silver resistance, of *E. coli*, 223
Southern hybridisation, 25, 145
Staphylococci
adherence factors, 135
carbonic anhydrase activity, 1
coagulase-negative, 19, 115, 135
S. aureus, adherence and survival, 9, 195
S. aureus, and fluoroquinolones, 15
S. aureus, hydrophobicity, 9
S. aureus, methicillin-resistant, 195
S. aureus, methicillin-sensitive, 195
S. aureus, in necrotic tumours, 207
S. aureus, "Oxford" strain, 195
S. epidermidis, in necrotic tumours, 207
S. epidermidis, in urinary tract infections, 135
S. hyicus plasmid, 201
S. hyicus, streptomycin resistance, 201
slime production, 135
S. saprophyticus, hydrophobicity, 19
S. saprophyticus, opsonic requirements for phagocytosis, 19
S. saprophyticus, in urinary tract infection, 135
variations in typing characteristics, 115
Streptococci
carbonic anhydrase activity, 1
β-haemolytic, 111
M-type, 111, 283
in necrotic tumours, 207
post-streptococcal acute glomerulonephritis, 111
provisional type, 111
S. pyogenes, pyrolysis-mass spectrometry, 283
Streptomycin resistance, of *S. hyicus*, 201

Taxon 13 strains
immunogenicity of outer membrane proteins, 55
Toxins
of *B. pertussis*, 173
of *C. diphtheriae*, 247
of *E. coli*, 73
Shiga-like toxin-I (Verotoxin 1), 255
Shiga toxin, 255
see also Cytotoxins; Endotoxin; Enterotoxin; Exotoxin
Toxoid, diphtheria, 247
Toxoplasma gondii
DNA, in polymerase chain reaction, 25
Trichomonads
effects of oestrogen, 227
oestrogen binding, 227
Trimethoprim resistance, of *E. coli*, 153, 159
Tumour necrosis factor, 217
Tumours, solid, bacteria from, 207
Typing methods
instability of staphylococcal characteristics, 115

Ultrasonication
extraction of cytotoxic necrotising factor, 73
Ureaplasmas
U. diversum, antigen expression, 163
U. diversum, monoclonal antibodies, 163
U. urealyticum, antigen expression, 163
U. urealyticum, monoclonal antibodies, 163
Urease "enzyme catch test", 163
Urinary tract infection
coagulase-negative staphylococci, 19
E. coli, 135
mouse model, 135
S. epidermidis, 135
S. saprophyticus, 135

Vaccines
against *B. pertussis*, 63, 173
against *P. multocida*, 55
Verotoxins, 73
rapid detection method, 255
Vibrio
V. cholerae, immunobiological relationships of toxins, 33
V. vulnificus, cytolytic action of haemolysin, 39
Vir cytotoxin, 73
Virulence factors
B. pertussis, 173
coagulase-negative staphylococci, 135
E. coli, 135
in urinary tract infections, 135

Waterborne infection
Cryptosporidium, 239
Western blotting, 275, 263
Whooping cough, 173

Yeasts
identification by electrophoretic analysis, 123
Yersinia enterocolitica
epidemiological typing, 179
restriction fragment length polymorphisms, 179

INDEX OF AUTHORS FOR VOLUME 32

ABDULLAHI M Z, GILMOUR N J L, POXTON I R. Outer membrane proteins of *Pasteurella multocida* type A and their doubtful role as protective antigens, 55
ADDY P A-K, *see* FARFEL *et al.*, 173
AKO-WAI A K, *see* LAMIKANRA *et al.*, 159
ALA'ALDEEN D A, WALL R A, BORRIELLO S P. Immunogenicity and cross-reactivity of the 70-Kda iron-regulated protein of *Neisseria meningitidis* in man and animals, 275
ALABI S A, ODUGBEMI T. Occurrence of *Aeromonas* species and *Pleisiomonas shigelloides* in patients with and without diarrhoea in Lagos, Nigeria, 45
AL MOFLEH I A, *see* AL TUWAIJRI *et al.*, 189
AL TUWAIJRI A S, AL MOFLEH I A, MAHMOUD A A. Effect of *Leishmania major* on human polymorphonuclear leucocyte function *in vitro*, 189
AMYES S G B, *see* LEWIN AND AMYES, 83
AMYES S G B, *see* PAYNE *et al.*, 131
AMYES S G B, *see* THOMSON *et al.*, 153
ANDERSEN J K, SAUNDERS N A. Epidemiological typing of *Yersinia enterocolitica* by analysis of restriction fragment length polymorphisms with a cloned ribosomal RNA gene, 179
ANDERSON R, *see* VAN RENSBURG *et al.*, 15
ANSORG R, *see* SCHMID *et al.*, 101
ARENDS J W, *see* LOFFELD *et al.*, 105
ASHKENAZI S, CLEARY T G. A method for detecting Shiga toxin and Shiga-like toxin-I in pure and mixed culture, 255

BABU SUSAN, JAIN N K, PRASAD G, BHATTACHARYA SUDHA, BHATTACHARYA A. Characterisation of cell-wall-derived polypeptide antigens from different species of *Mycobacterium*, 263
BANSAL V, *see* VINAYAK *et al.*, 87
BASSETT D C J, *see* REID *et al.*, 111
BAUDRAZ-ROSSELET F, *see* MONOD *et al.*, 123
BES M, *see* ETIENNE *et al.*, 115
BHASIN D K, *see* VINAYAK *et al.*, 87
BHATTACHARYA A, *see* BABU *et al.*, 263
BHATTACHARYA SUDHA, *see* BABU *et al.*, 263
BLOBEL H, *see* SCHWARZ AND BLOBEL, 201
BORRIELLO S P, *see* ALA'ALDEEN *et al.*, 275
BROOK I. Bacteria from solid tumours, 207
BRUN Y, *see* ETIENNE *et al.*, 115
BURJÁN PÁLMA, *see* MARÓDI *et al.*, 19
BUTLER L O, *see* NAFI *et al.*, 1

CARTER E J, *see* PRESTON *et al.*, 63
CARTER N D, *see* NAFI *et al.*, 1
CHAPMAN P A, RUSH BARBARA A. Efficiency of sand filtration for removing cryptosporidium oocysts from water, 243
CHAPMAN P A, RUSH BARBARA A, MCLAUCHLIN J. An enzyme immunoassay for detecting *Cryptosporidium* in faecal and environmental samples, 233
CHAPMAN P A, *see* RUSH *et al.*, 239
CLEARY T G, *see* ASHKENAZI AND CLEARY, 255
COLMAN G, *see* HALLAS *et al.*, 247
COLMAN G, *see* REID *et al.*, 111
COLOMBRITA D, RAVIZZOLA G, PINSI G, LI VIGNI R, PIRALI F, TURANO A. Rapid detection and identification of mycobacteria from blood of patients with acquired immune deficiency syndrome, 271.
CRICHTON PAMELA B, OLD D C. Salmonellae of serotypes Gallinarum and Pullorum grouped by biotyping and fimbrial-gene probing, 145

DE RYCKE J, *see* TABOURET AND DE RYCKE, 73
DOHERTY CATHERINE, *see* TREDGETT *et al.*, 169
DUCKWORTH GEORGIA J, JORDENS J ZOE. Adherence and survival properties of an epidemic methicillin-resistant strain of *Staphylococcus aureus* compared with those of methicillin-sensitive strains,195

ELLIOTT T S J, *see* MCTAGGART *et al.*,131
ETIENNE J, RENAUD F, BES M, BRUN Y, GREENLAND T B, FRENEY J, FLEURETTE J. Instability of characteristics amongst coagulase-negative staphylococci causing endocarditis, 115

FARFEL Z, KÖNEN STEPHANIE, WIERTZ E, KLAPMUTS R, ADDY P A-K, HANSKI E. Antibodies to *Bordetella pertussis* adenylate cyclase are produced in man during pertussis infection and after vaccination, 173
FLENDRIG J A, *see* LOFFELD *et al.*, 105
FLEURETTE J, *see* ETIENNE *et al.*, 115
FREEMAN R, GOODFELLOW M, GOULD F K, HUDSON S J, LIGHTFOOT N F. Pyrolysis-mass spectrometry (Py-MS) for the rapid epidemiological typing of clinically significant bacterial pathogens, 283
FRENEY J, *see* ETIENNE *et al.*, 115
FRENK E, *see* MONOD *et al.*, 123
FURUTA H, *see* YAMANAKA *et al.*, 39

GAWORZEWSKA EVA, *see* REID *et al.*, 111
GILMOUR N J L, *see* ABDULLAHI *et al.*, 55
GOODFELLOW M, *see* FREEMAN *et al.*, 283
GOODWIN C S, *see* PRULL *et al.*, 93
GOULD F K, *see* FREEMAN *et al.*, 283
GOVAN J R W, *see* TREDGETT *et al.*, 169
GREENLAND T B, *see* ETIENNE *et al.*, 115
GREWAL J S, TIWARI R P. Resistance to metal ions and antibiotics in *Escherichia coli* isolated from foodstuffs, 223

HALLAS G, HARRISON T G, SAMUEL D, COLMAN G. Detection of diphtheria toxin in culture supernates of *Corynebacterium diphtheriae* and *C. ulcerans* by immunoassay with monoclonal antibody, 247
HANSKI E, *see* FARFEL *et al.*, 173

HARRISON T G, *see* HALLAS *et al.*, 247
HOLLIMAN R E, *see* SAVVA *et al.*, 25
HUDSON S J, *see* FREEMAN *et al.*, 283

INESON R W, *see* RUSH *et al.*, 239

JACKSON S K, *see* STARK AND JACKSON, 217
Jain N K, *see* BABU *et al.*, 263
JEFFERY S, *see* NAFI *et al.*, 1
JOHNSON J D, *see* SAVVA *et al.*, 25
JOONE GISELA, *see* VAN RENSBURG *et al.*, 15
JORDENS J ZOE, *see* DUCKWORTH AND JORDENS, 195

Kaur U, *see* VINAYAK *et al.*, 87
KELLY C, *see* NAFI *et al.*, 1
KLAPMUTS R, *see* FARFEL *et al.*, 173
KOHADA A, *see* MIYAKE *et al.*, 9
KÖNEN STEPHANIE, *see* FARFEL *et al.*, 173

LAMIKANRA A, AKO-NAI A K, OLA J B. Transmissible trimethoprim resistance in strains of *Escherichia coli* isolated from cases of infantile diarrhoea, 159
LEWIN C S, AMYES S G B. Conditions required for the bactericidal activity of fleroxacin and pefloxacin against *Escherichia coli* KL16, 83
LEWIN C S, SMITH J T. Conditions required for the bactericidal activity of 4-quinolones against *Serratia marcescens*, 211
LEWIS G, *see* PRULL *et al.*, 93
LIGHTFOOT N F, *see* FREEMAN *et al.*, 283
LI VIGNI R, *see* COLOMBRITA *et al.*, 271
LOFFELD R J L F, STOBBERINGH E, SPREEUWEL J P VAN, FLENDRIG J A, ARENDS J W. The prevalence of anti-*Helicobacter (Campylobacter) pylori* antibodies in patients and healthy blood donors, 105

MCDONALD P J, *see* PRULL *et al.*, 93
MCLAUCHLIN J, *see* CHAPMAN *et al.*, 233
MCTAGGART LESLEY A, RIGBY R C, ELLIOTT T S J. The pathogenesis of urinary tract infections associated with *Escherichia coli, Staphylococcus saprophyticus* and *S. epidermidis*, 135
MAHMOUD A A, *see* AL TUWAIJRI *et al.*, 189
MARÓDI L, BURJÁN PÁLMA, ROZGONYI F. Opsonic requirements and surface hydrophobicity of novobiocin-resistant, coagulase-negative staphylococci, 19
MARRIOTT M S, *see* PAYNE *et al.*, 131
MILES R J, *see* NAFI *et al.*, 1
MILLERSHIP S E, *see* WANT AND MILLERSHIP, 49
MINAGI S, *see* MIYAKE *et al.*, 9
MIYAKE Y, SUGAI M, KOHADA A, MINAGI S, SUGINAKA H. Adherence of *Staphylococcus aureus* to cultured epidermal cells during differentiation, 9
MIYOSHI S, *see* YAMANAKA *et al.*, 39
MONOD M, PORCHET S, BAUDRAZ-ROSSELET F, FRENK E. The identification of pathogenic yeast strains by electrophoretic analysis of their chromosomes, 123
MORRIS J C, *see* SAVVA *et al.*, 25

MUMMAW N, *see* SUGARMAN AND MUMMAW, 227
Myles Alison D, *see* THIRKELL *et al.*, 163

NAFI B M, MILES R J, BUTLER L O, CARTER N D, KELLY C, JEFFERY S. Expression of carbonic anhydrase in neisseriae and other heterotrophic bacteria, 1

ODUGBEMI T, *see* ALABI AND ODUGBEMI, 45
OLA J B, *see* LAMIKANRA *et al.*, 159
OLD D C, *see* CRICHTON AND OLD, 145

Pankhurst Dagmar, *see* PRULL *et al.*, 93
PAYNE D J, MARRIOTT M S, AMYES S G B. Characterisation of a unique ceftazidime-hydrolysing β-lactamase, TEM-E2, 131
PINSI G, *see* COLOMBRITA *et al.*, 271
PIRALI F, *see* COLOMBRITA *et al.*, 271
POON-KING T, *see* REID *et al.*, 111
PORCHET S, *see* MONOD *et al.*, 123
POXTON I R, *see* ABDULLAHI *et al.*, 55
PRASAD G, *see* BABU *et al.*, 263
PRESTON N W, ZORGANI A A, CARTER E J. Location of the three major agglutinogens of *Bordetella pertussis* by immuno-electronmicroscopy, 63
PRULL H, GOODWIN C S, MCDONALD P J, LEWIS G, PANKHURST DAGMAR. Hydrophobic characterisation of *Helicobacter (Campylobacter) pylori*, 93

RAVIZZOLA G, *see* COLOMBRITA *et al.*, 271
RECKLINGHAUSEN G VON, *see* SCHMID *et al.*, 101
REID H F M, BASSETT D C J, GAWORZEWSKA EVA,, COLMAN G, POON-KING T. Streptococcal serotypes newly associated with epidemic post-streptococcal acute glomerulonephritis, 111
RENAUD F, *see* ETIENNE *et al.*, 115
RIGBY R C, *see* MCTAGGART *et al.*, 131
ROZGONYI F, *see* MARÓDI *et al.*, 19
RUSH BARBARA A, CHAPMAN P A, INESON R W. A probable waterborne outbreak of cryptosporidiosis in the Sheffield area, 239
RUSH BARBARA A, *see* CHAPMAN AND RUSH, 243
Rush Barbara A, *see* CHAPMAN *et al.*, 233

SAHA SETARUNNAHAR, SANYAL S C. Immunobiological relationships of the enterotoxins produced by cholera toxin gene-positive (CT^+) and -negative (CT^-) strains of *Vibro cholerae* O1, 33
SAMUEL D, *see* HALLAS *et al.*, 247
SANYAL S C, *see* SAHA AND SANYAL, 23
SAUNDERS N A, *see* ANDERSEN AND SAUNDERS, W
SAVVA D, MORRIS J C, JOHNSON J D, HOLLIMAN R E. Polymerase chain reaction for detection of *Toxoplasma gondii*, 25
SCHMID E N, RECKLINGHAUSEN G VON, ANSORG R. Bacteriophages in *Helicobacter (Campylobacter) pylori*, 101

SCHWARZ S, BLOBEL H. A new streptomycin-resistance plasmid from *Staphylococcus hyicus* and its structural relationship to other staphylococcal resistance plasmids, 201
SHANDIL R K, *see* VINAYAK *et al.*, 87
SHINODA S, *see* YAMANAKA *et al.*, 39
SINGH K, *see* VINAYAK *et al.*, 87
SMITH J T, *see* LEWIN AND SMITH, 211
SPREEUWEL J P VAN, *see* LOFFELD *et al.*, 105
STARK J M, JACKSON S K. Sensitivity to endotoxin is induced by increased membrane fatty-acid unsaturation and oxidant stress, 217
STOBBERINGH E, *see* LOFFELD *et al.*, 105
SUGAI M, *see* MIYAKE *et al.*, 9
SUGARMAN B, MUMMAW N. Oestrogen binding by and effect of oestrogen on trichomonads and bacteria, 227
SUGINAKA H, *see* MIYAKE *et al.*, 9
SUGIYAMA K, *see* YAMANAKA *et al.*, 39

TABOURET M, DE RYCKE J. Detection of cytotoxic necrotising factor (CNF) in extracts of *Escherichia coli* strains by enzyme-linked immunosorbent assay, 73
TAYLOR-ROBINSON D, *see* THIRKELL *et al.*, 163
THIRKELL D, MYLES ALISON D, TAYLOR-ROBINSON D. A comparison of four major antigens in five human and several animal strains of ureaplasmas, 163
THOMSON C J, YOUNG HILARY-KAY, AMYES S G B. N-terminal amino-acid sequence and subunit structure of the type IV trimethoprim-resistant plasmid-encoded dihydrofolate reductase, 153
TIWARI R P, *see* GREWAL AND TIWARI, 223
TREDGETT M W, DOHERTY CATHERINE, GOVAN J R W. Incidence of common pyocin types of *Pseudomonas aeruginosa* from patients with cystic fibrosis and chronic airways diseases, 169
TURANO A, *see* COLOMBRITA *et al.*, 271

VAN RENSBURG CONSTANCE E JANSEN, JOONE GISELA, ANDERSON R. Interactions of the oxygen-dependent antimicrobial system of the human neutrophil with difloxacin, ciprofloxacin, pefloxacin and fleroxacin in the intraphagocytic eradication of *Staphylococcus aureus*, 15
VINAYAK V K, SHANDIL R K, BANSAL V, SINGH K, BHASIN D K, KAUR U. Uses and limitations in the demonstration of specific circulating immune complexes in patients with amoebiasis, 87

WALL R A, *see* ALA'ALDEEN *et al.*, 275
WANT SUSAN V, MILLERSHIP S E. Effects of incorporating ampicillin, bile salts and carbohydrates in media on the recognition and selection of *Aeromonas* spp. from faeces, 49
WIERTZ E, *see* FARFEL *et al.*, 173

YAMANAKA H, SUGIYAMA K, FURUTA H, MIYOSHI S, SHINODA S. Cytolytic action of *Vibrio vulnificus* haemolysin on mast cells from rat peritoneal cavity, 93
YOUNG HILARY-KAY, *see* THOMSON *et al.*, 153

ZORGANI A A, *see* PRESTON *et al.*, 63